November 13, 2024 Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
November 7, 2024 Ironwood Pharmaceuticals Reports Third Quarter 2024 Results Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
October 28, 2024 Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024 Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
October 24, 2024 Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
August 29, 2024 Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
August 8, 2024 Ironwood Pharmaceuticals Reports Second Quarter 2024 Results Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
July 25, 2024 Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
May 30, 2024 Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 21, 2024 Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
May 9, 2024 Ironwood Pharmaceuticals Reports First Quarter 2024 Results Ironwood Pharmaceuticals Reports First Quarter 2024 Results
May 6, 2024 Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
May 1, 2024 Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024 Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
April 25, 2024 Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
March 28, 2024 Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
February 29, 2024 Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
February 23, 2024 Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
February 15, 2024 Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
February 1, 2024 Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
